103RD GENERAL ASSEMBLY

State of Illinois

2023 and 2024

HB3631

Introduced 2/17/2023, by Rep. Hoan Huynh

SYNOPSIS AS INTRODUCED:

215 ILCS 5/513b1

Amends the Pharmacy Benefit Managers Article of the Illinois Insurance Code. Provides that a pharmacy benefit manager shall not prohibit a pharmacist or pharmacy from, or indirectly punish a pharmacist or pharmacy for, making any written or oral statement or otherwise disclosing information to any federal, State, county, or municipal official, including the Director of Insurance or law enforcement, or before any State, county, or municipal committee, body, or proceeding under specified circumstances. Provides that the provisions apply to contracts entered into or renewed on or after July 1, 2023 (rather than July 1, 2022).

LRB103 30054 BMS 56477 b

A BILL FOR

HB3631

1 AN ACT concerning regulation.

2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

4 Section 5. The Illinois Insurance Code is amended by 5 changing Section 513b1 as follows:

6 (215 ILCS 5/513b1)

7 Sec. 513b1. Pharmacy benefit manager contracts.

8 (a) As used in this Section:

9 "340B drug discount program" means the program established
10 under Section 340B of the federal Public Health Service Act,
11 42 U.S.C. 256b.

"340B entity" means a covered entity as defined in 42 U.S.C. 256b(a)(4) authorized to participate in the 340B drug discount program.

15 "340B pharmacy" means any pharmacy used to dispense 340B 16 drugs for a covered entity, whether entity-owned or external.

17 "Biological product" has the meaning ascribed to that term18 in Section 19.5 of the Pharmacy Practice Act.

19 "Maximum allowable cost" means the maximum amount that a 20 pharmacy benefit manager will reimburse a pharmacy for the 21 cost of a drug.

22 "Maximum allowable cost list" means a list of drugs for 23 which a maximum allowable cost has been established by a - 2 - LRB103 30054 BMS 56477 b

1 pharmacy benefit manager.

Pharmacy benefit manager" means a person, business, or entity, including a wholly or partially owned or controlled subsidiary of a pharmacy benefit manager, that provides claims processing services or other prescription drug or device services, or both, for health benefit plans.

7 "Retail price" means the price an individual without 8 prescription drug coverage would pay at a retail pharmacy, not 9 including a pharmacist dispensing fee.

10 "Third-party payer" means any entity that pays for 11 prescription drugs on behalf of a patient other than a health 12 care provider or sponsor of a plan subject to regulation under 13 Medicare Part D, 42 U.S.C. 1395w-1017 et seq.

14 (b) A contract between a health insurer and a pharmacy 15 benefit manager must require that the pharmacy benefit 16 manager:

17 (1) Update maximum allowable cost pricing information18 at least every 7 calendar days.

19 (2) Maintain a process that will, in a timely manner,
20 eliminate drugs from maximum allowable cost lists or
21 modify drug prices to remain consistent with changes in
22 pricing data used in formulating maximum allowable cost
23 prices and product availability.

(3) Provide access to its maximum allowable cost list
 to each pharmacy or pharmacy services administrative
 organization subject to the maximum allowable cost list.

HB3631

1 Access may include a real-time pharmacy website portal to be able to view the maximum allowable cost list. As used in 2 3 this Section, "pharmacy services administrative organization" means an entity operating within the State 4 5 that contracts with independent pharmacies to conduct 6 business on their behalf with third-party payers. A 7 pharmacy services administrative organization may provide administrative services to pharmacies and negotiate and 8 9 enter into contracts with third-party payers or pharmacy 10 benefit managers on behalf of pharmacies.

(4) Provide a process by which a contracted pharmacy can appeal the provider's reimbursement for a drug subject to maximum allowable cost pricing. The appeals process must, at a minimum, include the following:

(A) A requirement that a contracted pharmacy has
16 14 calendar days after the applicable fill date to
17 appeal a maximum allowable cost if the reimbursement
18 for the drug is less than the net amount that the
19 network provider paid to the supplier of the drug.

(B) A requirement that a pharmacy benefit manager
must respond to a challenge within 14 calendar days of
the contracted pharmacy making the claim for which the
appeal has been submitted.

(C) A telephone number and e-mail address or
website to network providers, at which the provider
can contact the pharmacy benefit manager to process

- 4 - LRB103 30054 BMS 56477 b

1 and submit an appeal.

(D) A requirement that, if an appeal is denied, the pharmacy benefit manager must provide the reason for the denial and the name and the national drug code number from national or regional wholesalers.

6 (E) A requirement that, if an appeal is sustained, 7 the pharmacy benefit manager must make an adjustment 8 in the drug price effective the date the challenge is 9 resolved and make the adjustment applicable to all 10 similarly situated network pharmacy providers, as 11 determined by the managed care organization or 12 pharmacy benefit manager.

(5) Allow a plan sponsor contracting with a pharmacy benefit manager an annual right to audit compliance with the terms of the contract by the pharmacy benefit manager, including, but not limited to, full disclosure of any and all rebate amounts secured, whether product specific or generalized rebates, that were provided to the pharmacy benefit manager by a pharmaceutical manufacturer.

20 (6) Allow a plan sponsor contracting with a pharmacy
21 benefit manager to request that the pharmacy benefit
22 manager disclose the actual amounts paid by the pharmacy
23 benefit manager to the pharmacy.

(7) Provide notice to the party contracting with the
 pharmacy benefit manager of any consideration that the
 pharmacy benefit manager receives from the manufacturer

HB3631

2

3

4

5

HB3631 - 5 - LRB103 30054 BMS 56477 b

1 2 for dispense as written prescriptions once a generic or biologically similar product becomes available.

3 (c) In order to place a particular prescription drug on a 4 maximum allowable cost list, the pharmacy benefit manager 5 must, at a minimum, ensure that:

(1) if the drug is a generically equivalent drug, it 6 7 is therapeutically equivalent listed as and pharmaceutically equivalent "A" or "B" rated in the United 8 9 States Food and Drug Administration's most recent version 10 of the "Orange Book" or have an NR or NA rating by 11 Medi-Span, Gold Standard, or a similar rating by a 12 nationally recognized reference;

13 (2) the drug is available for purchase by each
14 pharmacy in the State from national or regional
15 wholesalers operating in Illinois; and

16

(3) the drug is not obsolete.

(d) A pharmacy benefit manager is prohibited from limiting a pharmacist's ability to disclose whether the cost-sharing obligation exceeds the retail price for a covered prescription drug, and the availability of a more affordable alternative drug, if one is available in accordance with Section 42 of the Pharmacy Practice Act.

(e) A health insurer or pharmacy benefit manager shall not
require an insured to make a payment for a prescription drug at
the point of sale in an amount that exceeds the lesser of:

26

(1) the applicable cost-sharing amount; or

HB3631 - 6 - LRB103 30054 BMS 56477 b

1

(2) the retail price of the drug in the absence of prescription drug coverage.

2

3 (f) Unless required by law, a contract between a pharmacy 4 benefit manager or third-party payer and a 340B entity or 340B 5 pharmacy shall not contain any provision that:

6 (1) distinguishes between drugs purchased through the 7 340B discount program and other drug drugs when 8 determining reimbursement or reimbursement methodologies, 9 or contains otherwise less favorable payment terms or 10 reimbursement methodologies for 340B entities or 340B 11 pharmacies when compared to similarly situated non-340B 12 entities;

13 (2) imposes any fee, chargeback, or rate adjustment
14 that is not similarly imposed on similarly situated
15 pharmacies that are not 340B entities or 340B pharmacies;

16 (3) imposes any fee, chargeback, or rate adjustment 17 that exceeds the fee, chargeback, or rate adjustment that 18 is not similarly imposed on similarly situated pharmacies 19 that are not 340B entities or 340B pharmacies;

20 (4) prevents or interferes with an individual's choice 21 to receive a covered prescription drug from a 340B entity 22 or 340B pharmacy through any legally permissible means, 23 except that nothing in this paragraph shall prohibit the of differing 24 establishment copayments or other 25 cost-sharing amounts within the benefit plan for covered 26 persons who acquire covered prescription drugs from a

- 7 -LRB103 30054 BMS 56477 b

HB3631

1

6

nonpreferred or nonparticipating provider;

2 (5) excludes a 340B entity or 340B pharmacy from a pharmacy network on any basis that includes consideration 3 of whether the 340B entity or 340B pharmacy participates 4 5 in the 340B drug discount program;

(6) prevents a 340B entity or 340B pharmacy from using 7 a drug purchased under the 340B drug discount program; or

(7) any other provision that discriminates against a 8 9 340B entity or 340B pharmacy by treating the 340B entity 10 or 340B pharmacy differently than non-340B entities or 11 non-340B pharmacies for any reason relating to the 12 entity's participation in the 340B drug discount program.

13 As used in this subsection, "pharmacy benefit manager" and "third-party payer" do not include pharmacy benefit managers 14 15 and third-party payers acting on behalf of a Medicaid program.

16 (g) A violation of this Section by a pharmacy benefit 17 manager constitutes an unfair or deceptive act or practice in the business of insurance under Section 424. 18

19 (h) A provision that violates subsection (f) in a contract 20 between a pharmacy benefit manager or a third-party payer and 21 a 340B entity that is entered into, amended, or renewed after 22 July 1, 2022 shall be void and unenforceable.

23 (i) A pharmacy benefit manager shall not prohibit a 24 pharmacist or pharmacy from, or indirectly punish a pharmacist 25 or pharmacy for, making any written or oral statement or otherwise disclosing information to any federal, State, 26

	HB3631 - 8 - LRB103 30054 BMS 56477 b
1	county, or municipal official, including the Director or law
2	enforcement, or before any State, county, or municipal
3	committee, body, or proceeding if:
4	(1) the recipient of the information represents that
5	it has the authority, to the extent provided by State or
6	federal law, to maintain proprietary information as
7	confidential; and
8	(2) before disclosure of information designated as
9	confidential the pharmacist or pharmacy:
10	(A) marks as confidential any document in which
11	the information appears; or
12	(B) requests confidential treatment for any oral
13	communication of the information.
14	This includes sharing any portion of the pharmacy benefit

14 <u>This includes sharing any portion of the pharmacy benefit</u> 15 <u>manager contract with the Director pursuant to a complaint or</u> 16 <u>a query regarding whether the contract is in compliance with</u> 17 <u>this Article.</u>

18 <u>(j)</u> (i) This Section applies to contracts entered into or 19 renewed on or after July 1, <u>2023</u> 2022.

20 <u>(k)</u> (j) This Section applies to any group or individual 21 policy of accident and health insurance or managed care plan 22 that provides coverage for prescription drugs and that is 23 amended, delivered, issued, or renewed on or after July 1, 24 2020.

25 (Source: P.A. 101-452, eff. 1-1-20; 102-778, eff. 7-1-22; 26 revised 8-19-22.)